S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

$9.10
-0.35 (-3.70%)
(As of 04/19/2024 ET)
Today's Range
$8.44
$9.46
50-Day Range
$6.69
$12.53
52-Week Range
$1.76
$15.21
Volume
4.52 million shs
Average Volume
2.94 million shs
Market Capitalization
$880.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.56

Arcutis Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
191.8% Upside
$26.56 Price Target
Short Interest
Bearish
19.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Arcutis Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$41,811 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.36 out of 5 stars

Medical Sector

607th out of 909 stocks

Pharmaceutical Preparations Industry

270th out of 427 stocks

ARQT stock logo

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Stock Price History

ARQT Stock News Headlines

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.8%
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arcutis Biotherapeutics Inc Ordinary Shares ARQT
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down to $12.49
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arcutis Biotherapeutics appoints CFO
ARQT May 2024 10.000 call
ATHA Apr 2024 2.500 put
ARQT Apr 2024 12.500 call
ARQT Apr 2024 5.000 call
ARQT Apr 2024 2.500 call
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
296
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$26.56
High Stock Price Target
$50.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+191.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-262,140,000.00
Net Margins
-439.79%
Pretax Margin
-434.57%

Debt

Sales & Book Value

Annual Sales
$59.61 million
Book Value
$0.94 per share

Miscellaneous

Free Float
76,773,000
Market Cap
$880.97 million
Optionable
Optionable
Beta
1.14

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 56)
    President, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 69)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 53)
    J.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 52)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 71)
    Chief Financial Officer
    Comp: $410.75k
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Ms. Latha Vairavan
    Vice President of Finance & Investor Relations
  • Ms. Courtney Barton (Age 41)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corporate Communications
  • Ms. Ayisha Jeter
    Head of Marketing & Market Access

ARQT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price target for 2024?

8 brokers have issued 1-year price targets for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $8.00 to $50.00. On average, they predict the company's stock price to reach $26.56 in the next year. This suggests a possible upside of 191.8% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2024?

Arcutis Biotherapeutics' stock was trading at $3.23 on January 1st, 2024. Since then, ARQT stock has increased by 181.7% and is now trading at $9.10.
View the best growth stocks for 2024 here
.

Are investors shorting Arcutis Biotherapeutics?

Arcutis Biotherapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 19,260,000 shares, an increase of 28.5% from the March 15th total of 14,990,000 shares. Based on an average daily volume of 4,760,000 shares, the short-interest ratio is currently 4.0 days.
View Arcutis Biotherapeutics' Short Interest
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.08. The business had revenue of $13.53 million for the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 294.85% and a negative net margin of 439.79%. During the same quarter in the previous year, the firm posted ($1.18) EPS.

What ETFs hold Arcutis Biotherapeutics' stock?

ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include AMI Asset Management Corp (0.36%), Los Angeles Capital Management LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARQT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners